ankyrin repeat domain 42Genealiases: PPP1R79 · SARP
Q-omics provides the consensus-scored ANKRD42 profile across patient tissues and cancer cell-line models. ANKRD42 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ANKRD42 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ANKRD42 RNA expression shows 20,337 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KICH, and ACC as cancer lineages where ANKRD42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD42 survival associations across molecular data types. ANKRD42 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD42 RNA expression–survival associations across cancer types. High ANKRD42 expression shows unfavorable associations in LGG, BLCA and KICH, but favorable associations in BRCA, KIRC and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for ANKRD42 RNA expression.
This table summarizes ANKRD42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD42 shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, BRCA, CHOL and STAD. The KICH box plot shows higher ANKRD42 RNA expression in normal versus tumor tissue (log2 FC = −1.075, t-test p < 0.001).
This table shows molecular features associated with ANKRD42 in patient tissues and cancer cell lines. In patient samples, ANKRD42 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
